Altered vascular microenvironment by bevacizumab in diabetic fibrovascular membrane

Retina

Volumn 33, Issue 5, 2013, Pages 957-963

  Nakao, Shintaro ^a   Ishikawa, Keijiro ^a   Yoshida, Shigeo ^a   Kohno, Ri Ichiro ^a   Miyazaki, Masanori ^a   Enaida, Hiroshi ^a   Kono, Toshihiro ^b   Ishibashi, Tatsuro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BEVACIZUMAB; CD34 ANTIGEN; CD45 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DRUG EFFECT; FIBROVASCULAR MEMBRANE; HUMAN; IMMUNOHISTOCHEMISTRY; MICROVASCULAR ENDOTHELIAL CELL; MYOFIBROBLAST; OCULAR BLOOD VESSEL; PERICYTE; PROTEIN EXPRESSION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELLULAR MICROENVIRONMENT; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOFIBROBLASTS; PERICYTES; RETINAL VESSELS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84877001054     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182753b41     Document Type: Article

References (21)

1. Ishibashi T. Cell biology of intraocular vascular diseases. Jpn J Ophthalmol 2000;44:323-324.
2. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006;26:1006-1013.
3. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695 e1691-1615.
4. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26:699-700.
5. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-216.
6. Arimura N, Otsuka H, Yamakiri K, et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 2009;116:921-926.
7. Forooghian F, Kertes PJ, Eng KT, et al. Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. Invest Ophthalmol Vis Sci 2010;51:2388-2392.
8. Kita T, Hata Y, Kano K, et al. Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: Possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor. Diabetes 2007;56:231-238.
9. Kohno R, Hata Y, Mochizuki Y, et al. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol 2010;150:223-229.e221.
10. Pattwell DM, Stappler T, Sheridan C, et al. Fibrous membranes in diabetic retinopathy and bevacizumab. Retina 2010;30: 1012-1016.
11. El-Sabagh HA, Abdelghaffar W, Labib AM, et al. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology 2011;118:636-641.
12. Kubota T, Morita H, Tou N, et al. Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab. Retina 2010;30:468-472.
13. Bochaton-PiallatML, Kapetanios AD, Donati G, et al. TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci 2000;41: 2336-2342.
14. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995;92:10457-10461.
15. Chakravarthy U, Stitt AW, McNally J, et al. Nitric oxide synthase activity and expression in retinal capillary endothelial cells and pericytes. Curr Eye Res 1995;14:285-294.
16. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-827.
17. Enaida H, Okamoto K, Fujii H, Ishibashi T. LSFG findings of proliferative diabetic retinopathy after intravitreal injection of bevacizumab. Ophthalmic Surg Lasers Imaging 2010;41 Online: E1- e3.
18. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7:513-520.
19. Nakao S, Kuwano T, Tsutsumi-Miyahara C, et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest 2005;115:2979-2991.
20. Nakao S, Zandi S, Lara-Castillo N, et al. Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis: Surprisingly similar impact on leukocyte infiltration. Invest Ophthalmol Vis Sci 2012;53:3296-3302.
21. Nakao S, Arima M, Ishikawa K, et al. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis. Invest Ophthalmol Vis Sci 2012;53:4323-4328.